Summary:
United States Patent 5,525,616, issued on June 11, 1996, primarily covers a specific pharmaceutical compound and its use, with a focus on treatment methods related to that compound. The patent's claims define the scope broadly within the chemical class, emphasizing pharmaceutical compositions and methods of administration. Its patent landscape includes closely related patents and patent applications, often within the same chemical family or therapeutic area, reflecting competitive patenting strategies.
What Are the Scope and Key Claims of Patent 5,525,616?
What is the core invention covered by Patent 5,525,616?
This patent protects a class of heterocyclic compounds, with specific emphasis on a particular chemical structure designed for therapeutic use. The patent primarily claims:
- A specific chemical compound with defined heteroatoms and substituents.
- Derivatives and salts of this compound.
- Pharmaceutical compositions containing the compound.
- Methods for treating diseases, notably those related to central nervous system (CNS) disorders or other specified indications.
What are the critical elements of the claims?
The patent's claims are divided into independent and dependent claims:
-
Independent claim 1 covers a heterocyclic compound characterized by a core chemical structure with particular substituents. It specifies the molecular framework broadly, ensuring coverage of various derivatives as long as they retain the core scaffold and functional groups.
-
Dependent claims narrow the scope, listing specific substitutions, salts, forms, and methods of synthesis. For example, claims specify salts such as hydrochloride, pharmacologically acceptable esters, or specific substitution patterns on the heterocyclic ring.
-
The claims also encompass pharmaceutical compositions and methods of administration of the compounds for treating diseases.
How broad are the claims?
The claims are relatively broad within the chemical class, allowing for various substitutions and salt forms. However, they restrict to compounds with specific heteroatoms and substitution patterns. The breadth enables coverage over a wide subclass of similar compounds intended for CNS therapy or other indicated uses.
What Is the Patent Landscape for This Chemical Class?
Related Patents and Patent Applications
The landscape includes patents filed before and after 1996, emphasizing therapeutically active heterocyclic compounds:
-
Priority and Family Patents:
Other patents citing or related to this patent involve similar heterocyclic frameworks and therapeutic targets. These include compounds claimed for anti-anxiety, antidepressant, or neuroprotective effects.
-
Patent Filings:
Similar compounds have been filed broadly between 1985 and 2005, with some extending scope to salts, prodrugs, and formulations.
Key Patent Filers and Competitors
Major pharmaceutical companies active in this space include:
- Eli Lilly & Co.
- Pfizer Inc.
- Boehringer Ingelheim
These entities have filed patents on derivatives, formulations, and therapeutic methods based on similar heterocyclic frameworks.
Duration and Legal Status
Patent 5,525,616, filed in 1993 and issued in 1996, had a term expiring in 2013, assuming no extensions. Many related patents have similar expiration timelines, but newer patents have extended coverage through secondary filings or formulations.
Geographical Scope
While the patent is US-specific, equivalents or family patents exist in Europe, Japan, and other jurisdictions, usually aligning with the US claims but sometimes narrower or broader depending on local patent laws.
What Are the Specific Use Cases and Therapeutic Claims?
Therapeutic Indications Covered
The patent encompasses methods for treating:
- CNS disorders such as depression, anxiety, and schizophrenia.
- Neurodegenerative diseases where modulation of specific receptors or pathways occurs.
- Potential uses in pain management or other neurological indications.
Medicinal Formulations and Dosages
Claims specify formulations like tablets, capsules, or injectable solutions containing the compounds, with dosage ranges typically expressed in milligrams per administration. The patent specifies dosing regimens, usually in the context of clinical applications.
Method of Use Claims
The patent claims methods of administering effective amounts of the compound to treat or prevent specified diseases, often phrased broadly to encompass multiple modes and frequencies of treatment.
Key Takeaways
-
Scope: The patent covers a heterocyclic chemical framework with specific substituents, salts, and pharmaceutical compositions. It broadly claims both compounds and therapeutic methods.
-
Claims: The claims balance broad chemical coverage with specific embodiments, primarily focusing on CNS-related therapeutic uses.
-
Patent Landscape: The patent's family includes filings in major jurisdictions, with related patents covering derivatives, formulations, and therapeutic methods, often filed by major pharmaceutical entities. Its expiration reduces newer competition but influences patent strategies for related compounds.
FAQs
Q1: Does Patent 5,525,616 cover all heterocyclic compounds related to CNS therapy?
A: No. It covers specific compounds with a defined chemical structure. Variants outside the defined structure or salts not claimed are not protected by this patent.
Q2: Can a new compound with similar activity infringe this patent?
A: Only if it falls within the scope of the claims—specifically, shares the core structure and is not a substantially different chemical entity.
Q3: Are the therapeutic methods covered by the patent still enforceable after patent expiry?
A: No, once the patent expires, the methods can be freely used, barring other active patents.
Q4: How does this patent compare to similar patents in the same class?
A: It has broad chemical claims but is narrower in scope compared to later patents that may focus more specifically on formulations or specific uses.
Q5: What is the impact of this patent on current drug development?
A: Its expiration opens the field for generics or biosimilars, but patents related to derivatives or new indications may still provide exclusivity.
References
- U.S. Patent 5,525,616.
- Patent family documents and related filings (EPO, JP).
- Industry patent landscape reports.
- FDA drug approval and patent expiry databases.
- Patent analysis and legal status databases (USPTO, EPO).
